Race Against Time: Enabling Access to Alzheimer’s Treatments

The Conference Board of Canada, March 1, 2022
Website by
(You must be signed in and entitled to rate this report)

Alzheimer’s disease is a growing concern in Canada. Scientific progress is shedding more light on its pathology and opening doors to new treatments. Are Canada’s healthcare systems able to support access?

Document Highlights

Dementia currently affects over half a million Canadians. By 2030, this will nearly double to 912,000. Alzheimer’s disease (AD), the most common cause of dementia, is the eighth leading cause of death in Canada, killing over 6,000 Canadians every year. In 2021, AD and other dementias will cost Canada an estimated $11.3 billion in both direct and indirect expenses. This is projected to rise to $16.6 billion by 2030.

People living with dementia have waited a long time for new treatments. Now, the era of disease-modifying therapies could transform Alzheimer’s care. “Race Against Time: Enabling Access to Alzheimer’s Treatments” looks at what’s needed to help Canada prepare for the looming dementia crisis.

COVID-19: Get all the insights

Price: $0

No charge, funded by The Conference Board of Canada and/or the research sponsor

Browse by...
Need Help?